# US 2008/0306116 A1 · Aryloxazole, aryloxadiazole and benzimidazole derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306116 A1
- Document ID: US20080306116A1
- Status: Published application
- Kind: A1
- Application number: 12/123,508
- Filed: 2008-05-20
- Published: 2008-12-11
- Earliest claimed: 2007-06-08
- Inventors: Andreas D. Christ; Rainer E. Martin; Peter Mohr
- Web page: https://patentgrep.com/patent/US20080306116A1

## CPC

- C07D 413/12: linked by a chain containing hetero atoms as chain links
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to compounds of the formula wherein X is O or NR8, Y is CR7 or N, and R1 to R8 are as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

## Claims

### Claim 1

A compound of formula I,
wherein
X is O or NR8, wherein R8 is hydrogen or C1-7-alkyl;
Y is CR7or N;
R1 is selected from the group consisting of ethyl, 2-fluoroethyl, isopropyl and isobutyl;
R2 is selected from the group consisting of hydrogen, C1-7-alkyl,
hydroxy, C1-7-alkoxy,
C3-7-cycloalkyl, —O—C3-7-cycloalkyl,
halogen, halogen-C1-7-alkyl,
—C(O)OR9, wherein R9 is C1-7-alkyl,
—NH—C(O)—R10, wherein R10 is C1-7alkyl, amino,
pyridyl, imidazolyl, triazolyl, pyrrolyl, phenyl, and
phenyl substituted by one to three substituents selected from the group consisting of halogen, halogen-C1-7-alkyl and halogen-C1-7-alkoxy;
R3 is selected from the group consisting of hydrogen, C1-7-alkoxy, amino,
—NH—C(O)—R11, wherein R11 is C1-7-alkyl,
—O-benzyl and —O-tetrahydropyranyl;
or R2 and R3 are bonded to each other to form a ring together with the carbon atoms they are attached to and R2 and R3 together are
—CH═CH—NH— or —CH═CH—C(CH3)2—O—;
R4 is selected from the group consisting of hydrogen, halogen, pyridyl and pyrimidyl;
R5 and R5′ independently from each other are selected from hydrogen or methyl;
one of R6 or R7 is phenyl or phenyl substituted by one to three substituents selected from the group consisting of
alogen, halogen-C1-7-alkyl, halogen-C1-7-alkoxy,
hydroxy, C1-7-alkoxy, hydroxy-C1-7-alkyl, hydroxy-C2-7-alkoxy,
di-hydroxy-C3-7alkoxy, C1-7-alkoxy-C2-7-alkoxy, C1-7alkoxy-hydroxy-C3-7-alkoxy,
C3-7-cycloalkyl-C1-7-alkoxy, C3-7-cycloalkoxy,
C1-7-alkyl, C3-7-cycloalkyl,
cyano, cyano-C1-7-alkoxy,
C1-7-alkylamino, di-C1-7-alkylamino, amino-C2-7-alkoxy, amino-C1-7-alkyl,
C1-7-alkylsulfonyl, —O—C1-7-alkylsulfonyl, C1-7-alkylsulfonyl-C2-7-alkoxy,
fluorophenyl, pyridyl, tetrazolyl and tetrazolyI-C1-7-alkoxy,
—C1-7-alkyl-C(O)NR12R13 or —O—C1-7-alkyl-C(O)NR12R13, wherein R11 and R12 are C1-7-alkyl,
—C1-7-alkyl-C(O)OR14, wherein R14 is C1-7-alkyl, and
—O—C1-7-alkyl-C(O)OR15, wherein R15 is C1-7-alkyl,
and the other one of R6 or R7 is hydrogen or absent in case Y is N;
or R6 and R7 are bonded to each other to form a ring together with the carbon atoms they are attached to and R6 and R7 together are —H═CH—CH═CH—;
and pharmaceutically acceptable salts thereof.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein R1 is ethyl or isopropyl.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein R2 is selected from the group consisting of hydrogen, Cl1-7-alkyl, hydroxy, C1-7-alkoxy, C3-7-cycloalkyl, —O—C3-7-cycloalkyl, halogen, halogen-C1-7-alkyl, amino, phenyl and phenyl substituted by one to three substituents selected from the group consisting of halogen, halogen-C1-7-alkyl and halogen-C1-7-alkoxy.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein R2 is selected from the group consisting of hydrogen, C1-7-alkyl, hydroxy, C1-7-alkoxy, halogen, amino and phenyl substituted by one to three substituents selected from the group consisting of halogen, halogen-C1-7-alkyl and halogen-C1-7-alkoxy.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein R2 is selected from the group consisting of halogen, amino and phenyl substituted by halogen.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein R2 is halogen.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein R3 is hydrogen or C1-7-alkoxy.

### Claim 8 (depends on 1)

The compound according to claim 1, wherein R3 is C1-7alkoxy.

### Claim 9 (depends on 1)

The compound according to claim 1, wherein R2 and R3 are bonded to each other to form a ring together with the carbon atoms they are attached to and R2 and R3 together are —CH═CH—C(CH3)2—O—.

### Claim 10 (depends on 1)

The compound according to claim 1, wherein R4 is hydrogen.

### Claim 11 (depends on 1)

The compound according to claim 1, wherein R5 and R5′ are hydrogen.

### Claim 12 (depends on 1)

The compound according to claim 1, wherein X is O and Y is N.

### Claim 13 (depends on 1)

The compound according to claim 1, wherein R6 is phenyl or phenyl substituted by one to three substituents selected from the group consisting of halogen, halogen-C1-7-alkyl, halogen-C1-7-alkoxy, hydroxy, C1-7-alkoxy, hydroxy-C1-7-alkyl, hydroxy-C3-7-alkoxy, di-hydroxy-C3-7-alkoxy, C1-7-alkoxy-C2-7-alkoxy, C1-7-alkoxy-hydroxy-C3-7-alkoxy, C3-7-cycloalkyl-C1-7-alkoxy, C3-7-cycloalkoxy, C1-7-alkyl, C3-7-cycloalkyl, cyano, cyano-C1-7-alkoxy, C1-7-alkylamino, di-C1-7-alkyl-amino, amino-C2-7-alkoxy, amino-C1-7-alkyl, C1-7-alkylsulfonyl, —O—C1-7-alkylsulfonyl, C1-7-alkylsulfonyl-C2-7alkoxy, fluorophenyl, pyridyl, tetrazolyl and tetrazolyl-C1-7-alkoxy, —C1-7-alkyl-C(O)NR12R13 or —O—C1-7-alkyl-C(O)NR12R13, wherein R11 and R12 are C1-7-alkyl, —C1-7-alkyl-C(O)OR14, wherein R14 is C1-7-alkyl, and —O—C1-7-alkyl-C(O)OR15,
wherein R15 is C1-7-alkyl.

### Claim 14 (depends on 1)

The compound according to claim 1, wherein R6 is phenyl or phenyl substituted by one to three substituents selected from the group consisting of halogen, halogen-C1-7-alkyl and C1-7-alkoxy.

### Claim 15 (depends on 1)

The compound according to claim 1, wherein X is NR8 and Y is CR7.

### Claim 16 (depends on 1)

The compound according to claim 1, wherein R8 is hydrogen or C1-7-alkyl and wherein R6 and R7 are bonded to each other to form a ring together with the carbon atoms they are attached to and R6 and R7 together are —CH═CH—CH═CH—.

### Claim 17 (depends on 1)

The compound according to claim 1, wherein X is O and Y is CR7.

### Claim 18 (depends on 17)

The compound according to claim 17, wherein one of R6 or R7 is phenyl or phenyl substituted by one to three substituents selected from the group consisting of halogen, halogen-C1-7-alkyl, halogen-C1-7-alkoxy, hydroxy, C1-7-alkoxy, hydroxy-C1-7-alkyl, hydroxy-C2-7-alkoxy, di-hydroxy-C3-7-alkoxy, C1-7-alkoxy-C2-7-alkoxy, C1-7-alkoxy-hydroxy-C3-7-alkoxy, C3-7-cycloalkyl-C1-7-alkoxy, C3-7-cycloalkoxy, C1-7-alkyl, C3-7-cycloalkyl, cyano, cyano-C1-7-alkoxy, C1-7-alkylamino, di-C1-7-alkyl-amino, amino-C2-7-alkoxy, amino-C1-7-alkyl, C1-7-alkylsulfonyl, —O—C1-7alkylsulfonyl, C1-7-alkylsulfonyl-C2-7-alkoxy, fluorophenyl, pyridyl, tetrazolyl and tetrazolyl-C1-7-alkoxy, —C1-7-alkyl-C(O)NR12R13 or —O—C1-7-alkyl-C(O)NR12R13, wherein R11 and R12 are C1-7-alkyl, —C1-7-alkyl-C(O)OR14, wherein R14 is C1-7-alkyl, and —O—C1-7-alkyl-C(O)OR15, wherein R15 is C1-7-alkyl,
and the other one of R6 or R7 is hydrogen.

### Claim 19 (depends on 17)

The compound according to claim 17, wherein R7 is hydrogen and R6 is phenyl or phenyl substituted by one to three substituents selected from the group consisting of halogen, halogen-C1-7-alkyl and C1-7-alkoxy.

### Claim 20 (depends on 17)

The compound according to claim 17, wherein R6 is hydrogen and R7 is phenyl or phenyl substituted by one to three substituents selected from the group consisting of halogen, halogen-C1-7-alkyl and C1-7-alkoxy.

### Claim 21 (depends on 1)

The compound according to claim 1, selected trom the group consisting of
[1-(3-ethoxy-4-methyl-benzyl)-piperidin-4-yl]-(3-phenyl-[1,2,4]oxadiazol-5-yl)-amine,
[1-(4-chloro-3-ethoxy-benzyl)-piperidin-4-yl]-(3-phenyl-[1,2,4]oxadiazol-5-yl)-amine,
2-ethoxy-4-[4-(3-phenyl-[1,2,4]oxadiazol-5-ylamino)-piperidin-1-ylmethyl]-phenol,
[1-(3-ethoxy-4-methoxy-benzyl)-piperidin-4-yl]-(3-phenyl-[1,2,4]oxadiazol-5-yl)-amine,
[1-(3-isobutoxy-4-methoxy-benzyl)-piperidin-4-yl]-(3-phenyl-[1,2,4]oxadiazol-5-yl)-amine,
{1-[3-(2-fluoro-ethoxy)-4-methoxy-benzyl]-piperidin-4-yl}-(3-phenyl-[1,2,4]oxadiazol-5-yl)-amine,
1-(8-ethoxy-2,2-dimethyl-2H-chromen-6-ylmethyl)-piperidin-4-yl]-(3-phenyl-[1,2,4]oxadiazol-5-yl)-amine,
[1-(3,5-diethoxy-4-fluoro-benzyl)-piperidin-4-yl]-(3-pheny-[1,2,4]oxadiazol-5-yl)-amine,
[1-(4-amino-3,5-diethoxy-benzyl)-piperidin-4-yl]-(3-phenyl-[1,2,4]oxadiazol-5-yl)-amine,
(1H-benzoimidazol-2-yl)-{1-[3-ethoxy-4-(1-ethyl-propoxy)-benzyl]-piperidin-4-yl}-amine,
[1-(4-chloro-3-ethoxy-benzyl)-piperidin-4-yl]-(1-methyl-1H-benzoimidazol-2-yl)-amine,
[1-(3-ethoxy-4-methoxy-benzyl)-piperidin-4-yl]-(1-methyl-1H-benzoimidazol-2-yl)-amine,
[1-(3,5-diisopropoxy-benzyl)-piperidin-4-yl]-(1-methyl-1H-benzoimidazol-2-yl)-amine,
[1-(3,5-diethoxy-4-fluoro-benzyl)-piperidin-4-yl]-(1-methyl-1H-benzoimidazol-2-yl)-amine,
[1-(2,6-diethoxy-4′-fluoro-biphenyl-4-ylmethyl)-piperidin-4-yl]-[4-(3-methoxy-phenyl)-oxazol-2-yl]-amine,
[1-(3,5-diethoxy-4-fluoro-benzyl)-piperidin-4-yl]-[4-(3-methoxy-phenyl)-oxazol-2-yl]-amine,
[1-(2,6-diethoxy-4′-fluoro-biphenyl-4-ylmethyl)-piperidin-4-yl]-[4-(4-fluoro-phenyl)-oxazol-2-yl]-amine,
[1-(2-ethoxy-4′-fluoro-biphenyl-4-ylmethyl)-piperidin-4-yl]-[4-(4-fluoro-phenyl)-oxazol-2-yl]-amine,
[1-(3,5-diethoxy-4-fluoro-benzyl)-piperidin-4-yl]-[4-(4-fluoro-phenyl)-oxazol-2-yl]-amine,
[1-(4-chloro-3,5-diethoxy-benzyl)-piperidin-4-yl]-[4-(3-methoxy-phenyl)-oxazol-2 -yl]-amine,
[1-(3-ethoxy-4-methyl-benzyl)-piperidin-4-yl]-[4-(3-methoxy-phenyl)-oxazol-2-yl]-amine,
[1-(3,5-diisopropoxy-benzyl)-piperidin-4-yl]-[4-(4-fluoro-phenyl)-oxazol-2-yl]-amine,
[1-(4-chloro-3,5-diethoxy-benzyl)-piperidin-4-yl]-[4-(4-fluoro-phenyl)-oxazol-2-yl]-amine,
[1-(2,6-diethoxy-4′-fluoro-biphenyl-4-ylmethyl)-piperidin-4-yl]-(4-phenyl-oxazol-2-yl)-amine,
[1-(4-chloro-3,5-diethoxy-benzyl)-piperidin-4-yl]-(4-phenyl-oxazol-2-yl)-amine,
[1-(3,5-diisopropoxy-benzyl)-piperidin-4-yl]-(4-phenyl-oxazol-2-yl)-amine,
[1-(4-chloro-3,5-diethoxy-benzyl)-piperidin-4-yl]-[4-(4-chloro-phenyl)-oxazol-2-yl]-amine,
[4-(4-chloro-phenyl)-oxazol-2-yl]-[1-(2,6-diethoxy-4′-fluoro-biphenyl-4-ylmethyl)-piperidin-4-yl]-amine,
[4-(4-chloro-phenyl)-oxazol-2-yl]-[1-(3,5-diethoxy-4-fluoro-benzyl)-piperidin-4-yl]-amine,
[1-(3,5-diethoxy-4-fluoro-benzyl)-piperidin-4-yl]-(4-phenyl-oxazol-2-yl)-amine,
[1-(2-ethoxy-4′-fluoro-biphenyl-4-ylmethyl)-piperidin-4-yl]-[5-(4-fluoro-phenyl)-oxazol-2yl]-amine,
[1-(2,6-diethoxy-440 -fluoro-biphenyl-4-ylmethyl)-piperidin-4-yl]-[5-(4-fluoro-phanyl)-oxazol-2-yl]-amine,
[1-(2,6-diethoxy-4′-fluoro-biphenyl-4-ylmethyl)-piperidin-4-yl]-(5-phenyl-oxazol-2-yl)-amine,
[1-(3,5-diethoxy-4-fluoro-benzyl)-piperidin-4-yl]-(5-pheny,-oxazol-2-yl)-amine,
[1-(3,5-diisopropoxy-benzyl)-piperidin-4-yl]-[5-(4-fluoro-phenyl)-oxazol-2-yl]-amine,
[1-(3,5-diethoxy-4-fluoro-benzyl)-piperidin-4-yl]-[5-(4-fluoro-phenyl)-oxazol-2-yl]-amine,
[1-(4-chloro-3,5-diethoxy-benzyl)-piperidin -4-yl]-(5-phenyl-oxazol-2-yl)-amine,
[1-(3-ethoxy-4-methyl-benzyl)-piperidin-4-yl]-(5-phenyl-oxazol-2-yl)-amine,
[1-(4-chloro-3,5-diehoxy-benzyl)-piperidin-4-yl]-[5-(4-fluoro-phenyl)-oxazol-2-yl]-amine,
[1-(2,6-diethoxy-4′-fluoro-biphenyl-4-ylmethyl)-piperidin-4-yl]-[5-(4 -methoxy-phenyl)-oxazol-2-yl]-amine,
[1-(4-chloro-3,5-diethoxy-benzyl)-piperidin-4-yl]-[5-(4-methoxy-phenyl)-oxazol-2-yl]-amine,
[1-(3-ethoxy-4-methyl-benzyl)-piperidin-4-yl]-[5-(4-methoxy-phenyl)-oxazol-2-yl]-amine,
[1-(3,5-diisopropoxy-benzyl)-piperidin-4-yl]-[5-(4-methoxy-phenyl)-oxazol-2-yl]-amine,
[1-(3,5-diethoxy-4-fluoro-benzyl)-piperidin-4-yl]-[5-(4-methoxy-phenyl)-oxazol-2-yl]-amine,
[1-(3-ethoxy-4-methyl-benzyl)-piperidin-4-yl]-[5-(4-fluoro-phenyl)-oxazol-2-yl]-amine,
[1-(3,5-diethoxy-4-methyl-benzyl)-piperidin-4-yl]-(5-phenyl-oxazol-2-yl)-amine,
[4-(4-chloro-phenyl)-oxazol-2-yl]-[1-(3-ethoxy-4-methyl-benzyl)-piperidin-4-yl]-amine,
[1-(3-ethoxy-4-methyl-benzyl)-piperidin-4-yl]-[4-(4-fluoro-phenyl)-oxazol-2-yl]-amine,
[1-(2,6-diethoxy-4′-fluoro-biphenyl-4-ylmethyl)-piperidin-4-yl]-[4-(4-trifluoromethyl-phenyl)-oxazol-2-yl]-amine,
and pharmaceutically acceptable salts thereof.

### Claim 22 (depends on 1)

The compound according to claim 1, selected from the group consisting of
[1-(4-amino-3,5-diethoxy-benzyl)-piperidin-4-yl]-(3-phenyl-[1,2,4]oxadiazol-5-yl)-amine,
[1-(3,5-diisopropoxy-benzyl)-piperidin-4-yl]-(1-methyl-1H-benzoimidazol-2-yl)-amine,
[1-(3,5-diethoxy-4-fluoro-benzyl)-piperidin-4-yl]-(1-methyl-1H-benzoimidazol-2-yl)-amine,
[1-(2,6-diethoxy4′-fluoro-biphenyl-4-ylmethyl)-piperidin-4-yl]-[4-(4-fluoro-phenyl)-oxazol-2-yl]-amine,
[1-(3,5-diethoxy-4-fluoro-benzyl)-piperidin-4-yl]-[4-(4-fluoro-phenyl)-oxazol-2-yl]-amine,
[1-(4-chloro-3,5-diethoxy-benzyl)-piperidin-4-yl]-(4-phenyl-oxazol-2-yl)-amine,
[1-(4-chloro-3,5-diethoxy-benzyl)-piperidin-4-yl]-[4-(4-chloro-phenyl)-oxazol-2-yl]-amine,
[1-(3,5-diethoxy-4-fluoro-benzyl)-piperidin-4-yl]-(4-phenyl-oxazol-2-yl)-amine,
[1-(4-chloro-3,5-diethoxy-benzyl)-piperidin-4-yl]-(5-pheny-oxazol-2-yl)-amine,
and pharmaceutically acceptable salts thereof.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

A process for the manufacture of compounds according to any one of claims 1 to 22, comprising the steps of:
a) reacting a piperidine of the formula
wherein X, Y and R6 are as defined in claim 1,
with an aldehyde of the formula
wherein R1 to R4 are as defined in claim 1,
by employing a reducing agent to obtain a compound of the formula
and, if desired, converting the compound of formula I into a pharmaceutically acceptable salt; or, alternatively,
b) alkylating a piperidine of the formula
wherein X, Y and R6 are as defined in claim 1,
with a compound of the formula
wherein R1 to R5 and R5′ are as defined in claim 1 and Hal means a leaving group, under basic conditions to obtain a compound or formula
and, if desired, converting the compound of formula I into a pharmaceutically acceptable salt; or, alternatively,
c) coupling an amine of the general formula
wherein R1 to R5 and R5′ are as defined in claim 1,
with a cloride of the formula
wherein X, Y and R6 are as defined herein before, by employing microwave conditions in the presence of a base to obtain a compound of the formula
and, if desired, converting the compound of formula I into a pharmaceutically acceptable salt.

### Claim 24 (depends on 1)

A pharmaceutical composition, comprising a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier and/or adjuvant.
